{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T05:22:46Z","timestamp":1649136166925},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.remn.2018.09.006","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T06:43:26Z","timestamp":1540881806000},"page":"22-28","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Valoraci\u00f3n de factores predictivos de positividad en PET con 68Ga-PSMA-11 en el c\u00e1ncer de pr\u00f3stata"],"prefix":"10.1016","volume":"38","author":[{"given":"A.L.","family":"Guti\u00e9rrez-Cardo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"P\u00e9rez Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.F.","family":"Garc\u00eda-Arg\u00fcello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"L\u00f3pez Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.E.","family":"Lillo Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Valdivielso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remn.2018.09.006_bib0150","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer."},{"key":"10.1016\/j.remn.2018.09.006_bib0155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.semnuclmed.2010.08.005","article-title":"PET\/CT imaging and radioimmunotherapy of prostate cancer","volume":"41","author":"Bouchelouche","year":"2011","journal-title":"Semin Nucl Med."},{"key":"10.1016\/j.remn.2018.09.006_bib0160","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.urolonc.2012.04.016","article-title":"Prostate-specific membrane antigen-based imaging","volume":"31","author":"Osborne","year":"2013","journal-title":"Urol Oncol Semin Orig Investig."},{"key":"10.1016\/j.remn.2018.09.006_bib0165","first-page":"1807","article-title":"Expression of the prostate-specific membrane antigen","volume":"54","author":"Israeli","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.remn.2018.09.006_bib0170","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.canlet.2005.05.021","article-title":"Tissue-specificity of prostate specific antigens: Comparative analysis of transcript levels in prostate and non-prostatic tissues","volume":"236","author":"Cunha","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.remn.2018.09.006_bib0175","doi-asserted-by":"crossref","first-page":"67S","DOI":"10.2967\/jnumed.116.186767","article-title":"Prostate-specific membrane antigen ligands for imaging and therapy","volume":"58","author":"Eiber","year":"2017","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remn.2018.09.006_bib0180","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12149-016-1078-7","article-title":"Acquisition with 11C-choline and 18F-fluorocholine PET\/CT for patients with biochemical recurrence of prostate cancer: A systematic review and meta-analysis","volume":"30","author":"Von Eyben","year":"2016","journal-title":"Ann Nucl Med."},{"key":"10.1016\/j.remn.2018.09.006_bib0185","doi-asserted-by":"crossref","first-page":"38S","DOI":"10.2967\/jnumed.115.169748","article-title":"Evaluation of prostate cancer with 11C- and 18F-choline PET\/CT: Diagnosis and initial staging","volume":"57","author":"Nitsch","year":"2016","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remn.2018.09.006_bib0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remn.2018.09.006_bib0195","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/ph7070779","article-title":"Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: A new PET tracer for imaging of prostate cancer","volume":"7","author":"Eder","year":"2014","journal-title":"Pharmaceuticals."},{"key":"10.1016\/j.remn.2018.09.006_bib0200","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","article-title":"68Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0","volume":"44","author":"Fendler","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remn.2018.09.006_bib0205","first-page":"130","article-title":"La PET\/TC con 68Ga-PSMA en el c\u00e1ncer de pr\u00f3stata","volume":"37","author":"Garc\u00eda Garz\u00f3n","year":"2018","journal-title":"Rev Esp Med Nucl Imagen Mol."},{"key":"10.1016\/j.remn.2018.09.006_bib0210","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s00259-017-3780-7","article-title":"Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging","volume":"44","author":"Sheikhbahaei","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remn.2018.09.006_bib0215","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2967\/jnumed.117.191031","article-title":"PSMA ligands for PET imaging of prostate cancer","volume":"58","author":"Schwarzenboeck","year":"2017","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remn.2018.09.006_bib0220","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00345-018-2182-1","article-title":"68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: A systematic review","volume":"36","author":"Corfield","year":"2018","journal-title":"World J Urol."},{"key":"10.1016\/j.remn.2018.09.006_bib0225","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00259-012-2069-0","article-title":"[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: Comparison with 18F-FECH","volume":"39","author":"Afshar-Oromieh","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remn.2018.09.006_bib0230","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2967\/jnumed.116.183483","article-title":"The clinical impact of additional late PET\/CT imaging with 68Ga-PSMA-11 (HBED-CC) in the siagnosis of prostate cancer","volume":"58","author":"Afshar-Oromieh","year":"2017","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remn.2018.09.006_bib0235","first-page":"48","article-title":"Three-phase 18F-fluorocholine PET\/CT in the evaluation of prostate cancer recurrence","author":"Steiner","year":"2008","journal-title":"Nuklearmedizin."},{"key":"10.1016\/j.remn.2018.09.006_bib0240","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00259-015-3240-1","article-title":"Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET\/CT in relation to PSA levels PSA doubling time and Gleason score","volume":"43","author":"Verburg","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remn.2018.09.006_bib0245","first-page":"223","article-title":"Correlaci\u00f3n entre el volumen molecular tumoral evaluado con PET\/TC con 68 Ga-PSMA y los niveles de ant\u00edgeno prost\u00e1tico espec\u00edfico","volume":"37","author":"Medina-Ornelas","year":"2018","journal-title":"Rev Esp Med Nucl Imagen Mol."},{"key":"10.1016\/j.remn.2018.09.006_bib0250","article-title":"PSA levels as a predictor of 68Ga PSMA PET\/CT positivity in patients with prostate cancer?","author":"Soydal","year":"2018","journal-title":"Q J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remn.2018.09.006_bib0255","doi-asserted-by":"crossref","first-page":"14630","DOI":"10.18632\/oncotarget.24318","article-title":"Trigger pSA predicting recurrence from positive choline PET\/CT with prostate cancer after initial treatment","volume":"9","author":"Wei","year":"2018","journal-title":"Oncotarget."},{"key":"10.1016\/j.remn.2018.09.006_bib0260","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","article-title":"Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy","volume":"56","author":"Morigi","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.remn.2018.09.006_bib0265","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1007\/s00259-015-3306-0","article-title":"PET\/CT with 18F-choline after radical prostatectomy in patients with PSA\u22642ng\/ml. Can PSA velocity and PSA doubling time help in patient selection?","volume":"43","author":"Chiaravalloti","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remn.2018.09.006_bib0270","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"Afshar-Oromieh","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remn.2018.09.006_bib0275","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00259-017-3848-4","article-title":"PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and\/or enzalutamide. A retrospective analysis of overall survival","volume":"45","author":"Rahbar","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remn.2018.09.006_bib0280","article-title":"Actual impact of 68 Ga-PSMA-11 PET\/CT on the management of prostate cancer patients with biochemical recurrence","volume":"59","author":"Calais","year":"2017","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remn.2018.09.006_bib0285","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","article-title":"Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer","volume":"17","author":"Dietlein","year":"2015","journal-title":"Mol Imaging Biol."}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253654X18301586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253654X18301586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T12:21:23Z","timestamp":1547122883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253654X18301586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S2253654X18301586"],"URL":"https:\/\/doi.org\/10.1016\/j.remn.2018.09.006","relation":{},"ISSN":["2253-654X"],"issn-type":[{"value":"2253-654X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valoraci\u00f3n de factores predictivos de positividad en PET con 68Ga-PSMA-11 en el c\u00e1ncer de pr\u00f3stata","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2018.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}